Table 3.
Patient demographic and clinical characteristics by risk group (N = 124)
| Patient characteristic | Group A Nonthoracic primary* and BRD3- or NSD3-NUT | Group B Nonthoracic primary* and BRD4-NUT | Group C Thoracic primary |
|---|---|---|---|
| (n = 12) | (n = 45) | (n = 67) | |
| Median OS (95% CI), mo | 36.5 (12.5 to NR) | 10 (7 to 14.6) | 4.4 (3.5 to 5.6) |
| 2-y OS (95% CI), % | 64 (30 to 85) | 28 (15 to 42) | 5 (1 to 14) |
| Long-term survivors (≥3 y), no. (%) | 5 of 12 (42) | 7 of 45 (16) | 0 of 67 (0) |
| Median age at initial cancer diagnosis (range), y | 27.0 (13.4–54.6) | 21.9 (0.1–71.4) | 23.7 (5.8–68.3) |
| No. | 12 | 42 | 59 |
| Age at initial cancer diagnosis, no. (%), y | |||
| <18 | 5 of 12 (42) | 19 of 42 (45) | 19 of 59 (32) |
| ≥18 | 7 of 12 (58) | 23 of 42 (55) | 40 of 59 (68) |
| Unknown | 0 | 3 | 8 |
| Sex, no. (%) | |||
| Male | 8 of 12 (67) | 19 of 45 (42) | 36 of 67 (54) |
| Female | 4 of 12 (33) | 26 of 45 (58) | 31 of 67 (46) |
| Primary tumor site, no. (%) | |||
| Thoracic | 0 of 12 (0) | 0 of 45 (0) | 67 of 67 (100) |
| Head and neck | 9 of 12 (75) | 40 of 45 (89) | 0 of 67 (0) |
| Bone and soft tissue* | 3 of 12 (25) | 3 of 45 (7) | 0 of 67 (0) |
| Other site (kidney) | 0 of 12 (0) | 2 of 45 (4) | 0 of 67 (0) |
| Histological type, no. (%) | |||
| Carcinoma with squamous differentiation | 5 of 12 (42) | 16 of 43 (37) | 21 of 67 (31) |
| Carcinoma without squamous differentiation | 7 of 12 (58) | 24 of 43 (56) | 36 of 67 (54) |
| Other histology | 0 of 12 (0) | 3 of 43 (7) | 10 of 67 (15) |
| Unknown | 0 | 2 | 0 |
| Tumor diameter at diagnosis, no. (%), cm | |||
| <6 | 5 of 7 (71) | 18 of 27 (67) | 18 of 45 (40) |
| ≥6 | 2 of 7 (29) | 9 of 27 (33) | 27 of 45 (60) |
| Unknown | 5 | 18 | 22 |
| Lymph node or organ metastasis at the baseline, no. (%) | |||
| Yes | 4 of 8 (50) | 27 of 36 (75) | 58 of 62 (94) |
| No | 4 of 8 (50) | 9 of 36 (25) | 4 of 62 (6) |
| Unknown | 4 | 9 | 5 |
| Initial treatment sequence, no. (%) | |||
| Chemotherapy ± subsequent treatment | 5 of 10 (50) | 9 of 41 (22) | 25 of 55 (45) |
| Radiation ± concurrent chemotherapy ± subsequent treatment | 2 of 10 (20) | 11 of 41 (27) | 18 of 55 (33) |
| Surgery ± subsequent treatment | 3 of 10 (30) | 21 of 41 (51) | 12 of 55 (22) |
| None or unknown | 2 | 4 | 12 |
| Microscopic margins involved (in any surgery), no. (%)† | |||
| Yes | 7 of 9 (78) | 7 of 12 (58) | 6 of 7 (86) |
| No | 2 of 9 (22) | 5 of 12 (42) | 1 of 7 (14) |
| Unknown | 1 | 14 | 10 |
| Any gross residual disease postoperatively (in any surgery), no. (%)† | |||
| Yes | 4 of 10 (40) | 11 of 19 (58) | 11 of 12 (92) |
| No | 6 of 10 (60) | 8 of 19 (42) | 1 of 12 (8) |
| Unknown | 0 | 7 | 5 |
*
Nonthoracic primary tumors include head and neck, bone, soft tissue, and other sites. Bone and soft tissue primary tumor include chest wall soft tissue, soft tissue mass, right hip bone, left scapula or shoulder, right chest soft tissue, soft tissue, occipital scalp soft tissue, iliac bone, temporal region soft tissue mass. CI = confidence interval; OS = overall survival; NR = not reported.
†
For patients with surgery and known data.